Executive Bureau

The PIC/S Chairperson is assisted in his/her task by the PIC/S Deputy Chairperson, the immediate past PIC/S Chairperson, the Chairs of Sub-Committees and the PIC/S Secretary (the latter with no voting right). Together they constitute the Executive Bureau (EB). 

Composition of PIC/S Executive Bureau (EB) for the period 2026-2027:

• Ms Kathleen Sinninger (US FDA), PIC/S Chairperson;
• Mr Gwylim Janssens (Netherlands / IGJ), PIC/S Deputy Chairperson and Chair of the Sub-Committee on Training (SCT);
• Mr Jacques Morénas (France / ANSM), immediate past PIC/S Chairperson;
• Ms Ying-Hua (Ellen) Chen (Chinese Taipei / TFDA), Chair of the Sub-Committee on Budget, Risk and Audit (SCB);
• Mr Roel Op den Camp (Switzerland / Swissmedic), Chair of the Sub-Committee on Strategic Development (SCSD);
• Ms Ana Carolina Moreira Araújo (Brazil / ANVISA), Chair of the Sub-Committee on Communication (SC COM);
• Ms Virginie Waysbaum (France / ANSM), Chair of the Sub-Committee on Compliance (SCC);
• Ms Nicole Proctor (Canada / ROEB), Chair of the Sub-Committee on Expert Circles (SCEC); and
• Mr Marco Paolo Fulfaro (Italy / AIFA), Chair of the Sub-Committee on GM(D)P Harmonisation (SCH).

The mandate of the PIC/S Executive Bureau is defined in the PIC Scheme and provides that it shall meet in between meetings of the Committee and as often as necessary in order to:

• monitor the Scheme’s activities;
• review the annual budget in line with the Financial Rules;
• propose strategic orientations and facilitate decision making;
• supervise the Secretariat and act as an employer for its staff.

The Executive Bureau reports to the PIC/S Committee. It has its own Rules of Procedure and usually meets back-to-back with the PIC/S Committee.